肝癌診斷市場規模、佔有率和成長分析：按檢測類型、癌症類型、最終用戶和地區分類－2026-2033年產業預測

2024 年全球肝癌診斷市場價值為 15.2 億美元，預計到 2033 年將從 2025 年的 16.7 億美元成長至 35.2 億美元，預測期（2026-2033 年）的複合年成長率為 9.82%。

全球肝癌診斷市場正經歷顯著成長，這主要得益於肝癌和慢性肝病的高發生率，以及人們對透過先進篩檢策略進行早期檢測的日益關注。分子和影像技術的創新，以及液態生物檢體解決方案的普及，正在提高診斷準確性和患者管理水平。對循環腫瘤DNA (ctDNA) 和人工智慧驅動的放射診斷平台的大量投資進一步推動了該市場的發展。此外，對預防性腫瘤學的日益重視，以及對肝細胞癌和慢性肝炎等疾病進行有效監測的需求不斷成長，也為市場拓展提供了更多機會。然而，高成本、進入問題和監管障礙等挑戰可能會阻礙市場進一步滲透。

全球肝癌診斷市場按檢測類型、癌症類型、最終用戶和地區進行細分。依檢測類型分類，市場分為肝功能檢查（LFT）、腫瘤標記檢測（AFP）、影像學檢查（CT、MRI、超音波）、切片檢查和液態生物檢體。依癌症類型分類，市場分為肝細胞癌（HCC）、膽管癌和轉移性肝癌。依最終用戶分類，市場分為醫院、診斷檢查室和癌症中心。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球肝癌診斷市場成長要素

全球肝癌診斷市場的主要促進因素之一是肝癌發生率的上升。這主要是由於肝炎感染率的增加、過度飲酒以及肥胖和相關METABOLIC INC.發病率的上升所致。隨著人們對肝病認知的提高，對早期、準確診斷程序的需求也日益成長。先進的影像技術，以及生物標記識別和分子診斷技術，正在提高診斷的準確性，醫療專業人員也越來越積極地採用這些創新解決方案。這種轉變對於制定有效的治療方案和改善患者預後至關重要，從而顯著推動了市場成長。

全球肝癌診斷市場面臨的限制因素

全球肝癌診斷市場的主要限制因素之一是診斷程序和先進影像技術的高昂成本。這些診斷方法帶來的經濟負擔可能會限制許多患者，特別是中低收入地區的患者獲得治療的機會。此外，大眾對肝癌症狀缺乏認知和了解，可能導致診斷延誤，進一步增加治療和照護的難度。這些因素共同阻礙了市場擴張，並可能導致醫療機構在投資昂貴的診斷工具方面猶豫不決，從而影響肝癌患者的整體治療效果和存活率。

全球肝癌診斷市場趨勢

在全球肝癌診斷市場中，液態生物檢體技術的應用正顯著成長，這主要得益於對微創診斷方法日益成長的需求。這些進步有望實現更早期的疾病檢測和更有效的疾病監測，最終改善患者的預後。診斷公司、醫療機構和保險公司之間的合作正在推動液態生物檢體與傳統影像和切片檢查方法的融合，從而最佳化診斷準確性。這一趨勢著重於改進檢測方法和標準化樣本製備流程，以促進臨床應用，最終目標是減輕患者的負擔，並幫助醫療專業人員做出更明智的臨床決策。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肝癌診斷市場規模：依檢測類型分類

• 肝功能檢查（LFTs）
• 腫瘤標記檢測（AFP）
• 診斷影像（CT）
• MRI
• 超音波
• 切片檢查
• 液態生物檢體

全球肝癌診斷市場規模：依癌症類型分類

• 肝細胞癌（HCC）
• 膽管癌
• 轉移性肝癌

全球肝癌診斷市場規模：依最終用戶分類

• 醫院
• 診斷實驗室
• 癌症中心

全球肝癌診斷市場規模：按地區分類

• 亞太地區
• 北美洲
• 歐洲

全球肝癌診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche Diagnostics
• Siemens Healthineers
• Abbott Laboratories
• Beckman Coulter（Danaher）
• bioMerieux SA
• Foundation Medicine（Roche）
• Guardant Health
• Exact Sciences
• Grail Inc.（Illumina）
• Bio-Rad Laboratories
• Quest Diagnostics
• Labcorp
• NeoGenomics Laboratories
• Burning Rock Biotech
• Caris Life Sciences
• Tempus Labs
• Sorrento Therapeutics
• EarlySense
• Trovagene Inc.
• Cynvenio Biosystems

結論與建議

Global Liver Cancer Diagnostics Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 3.52 Billion by 2033, growing at a CAGR of 9.82% during the forecast period (2026-2033).

The global liver cancer diagnostics market is experiencing significant growth driven by the high prevalence of liver cancer and chronic liver ailments, coupled with an increasing focus on early detection through advanced screening initiatives. Innovations in molecular diagnostics and imaging technologies, along with a rise in liquid biopsy solutions, are enhancing diagnostic accuracy and patient management. Key investments in circulating tumor DNA and AI-based radiology platforms further bolster this market. Additionally, the emphasis on preventive oncology, combined with a rising need for effective surveillance of conditions like hepatocellular carcinoma and chronic hepatitis infections, contributes to expanding market opportunities. Nevertheless, challenges such as high costs, accessibility issues, and regulatory hurdles may hinder broader market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cancer Diagnostics Market Segments Analysis

Global liver cancer diagnostics market is segmented by test type, cancer type, end-user,and region. Based on test type, the market is segmented into Liver Function Tests (LFTs), Tumor Marker Tests (AFP), Imaging (CT, MRI, Ultrasound), biopsy, and liquid biopsy. Based on cancer type, the market is segmented into Hepatocellular Carcinoma (HCC),Cholangiocarcinoma,and metastatic liver cancer. Based on end-user, the market is segmented into hospitals, diagnostic labs,and cancer centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America,and the Middle East & Africa.

Driver of the Global Liver Cancer Diagnostics Market

One of the key market drivers for the Global Liver Cancer Diagnostics Market is the rising prevalence of liver cancer, largely attributed to increasing rates of hepatitis infections, heavy alcohol consumption, and the rising incidence of obesity and associated metabolic syndromes. As awareness regarding liver disease expands, there is a growing demand for early and accurate diagnostic procedures. Advanced imaging technologies, along with biomarker identification and molecular diagnostics, are enhancing diagnostic accuracy, leading healthcare providers to adopt these innovative solutions more readily. This shift is crucial for effective treatment planning and improving patient outcomes, thereby driving market growth significantly.

Restraints in the Global Liver Cancer Diagnostics Market

One key market restraint for the global liver cancer diagnostics market is the high cost of diagnostic procedures and advanced imaging technologies. The financial burden associated with these diagnostic methods can limit accessibility for many patients, particularly in low- and middle-income regions. Additionally, the lack of awareness and understanding of liver cancer symptoms among the general population can lead to delayed diagnoses, further complicating treatment and care. These factors collectively hinder the expansion of the market, as healthcare providers may be reluctant to invest in costly diagnostic tools, thus impacting overall patient outcomes and survival rates in liver cancer cases.

Market Trends of the Global Liver Cancer Diagnostics Market

The Global Liver Cancer Diagnostics market is witnessing a significant shift towards the adoption of liquid biopsy techniques, driven by a growing demand for minimally invasive diagnostic options. These advancements promise earlier detection and more effective disease monitoring, enhancing patient outcomes. Collaborative efforts among diagnostic firms, healthcare providers, and insurance companies are paving the way for integrating liquid biopsies alongside traditional imaging and biopsy methods, thereby optimizing diagnostic accuracy. This trend focuses on refining assays and standardizing pre-analytical processes to streamline clinical integration, ultimately reducing patient discomfort and empowering healthcare professionals in making informed clinical decisions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Liver Cancer Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Liver Function Tests (LFTs)
• Tumor Marker Tests (AFP)
• Imaging (CT)
• MRI
• Ultrasound
• Biopsy
• Liquid Biopsy

Global Liver Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Hepatocellular Carcinoma (HCC)
• Cholangiocarcinoma
• Metastatic Liver Cancer

Global Liver Cancer Diagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Labs
• Cancer Centers

Global Liver Cancer Diagnostics Market Size by Region & CAGR (2026-2033)

• Market Overview
• Asia-Pacific
• North America
• Europe

Global Liver Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Cancer Type, End-User, Region)
  • US
  • Canada
• Europe (Test Type, Cancer Type, End-User, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Cancer Type, End-User, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Cancer Type, End-User, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Cancer Type, End-User, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grail Inc. (Illumina)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Burning Rock Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus Labs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EarlySense
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trovagene Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynvenio Biosystems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations